1. Pink Sheet
  2. >>Market Access

Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake

 
• By Cathy Kelly

Agency cites possible demonstration in response to HHS Office of Inspector General report urging reimbursement reforms to spur greater use of biosimilars and lower costs for Medicare and beneficiaries.

Biosimilar Uptake Needs A Reimbursement Boost, OIG Concludes • Source: Shutterstock

The Centers for Medicare and Medicaid Services is conducting research to determine how demonstration projects could be used to test ways to lower beneficiary and program spending on drugs and incentivize the use of biosimilar and generic drugs, the agency told the Health and Human Services Department Office of Inspector General in response to a recent OIG report on the uptake of biosimilars in Medicare Part B.

Released 2 October, the report recommends that CMS pursue “one or more” payment changes for biosimilars and their reference products to reduce Part B and enrollee spending.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 
• By Lauren Flynn Kelly

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.